Inc Amgen Net Worth

The estimated Net Worth of Inc Amgen is at least $4 Miliardo dollars as of 10 September 2021. Inc Amgen owns over 165,529 units of BeiGene Ltd stock worth over $3,999,983,792 and over the last 4 years Inc sold BGNE stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Inc Amgen BGNE stock SEC Form 4 insiders trading

Inc has made over 1 trades of the BeiGene Ltd stock since 2021, according to the Form 4 filled with the SEC. Most recently Inc bought 165,529 units of BGNE stock worth $49,999,690 on 10 September 2021.

The largest trade Inc's ever made was buying 165,529 units of BeiGene Ltd stock on 10 September 2021 worth over $49,999,690. On average, Inc trades about 23,647 units every 0 days since 2020. As of 10 September 2021 Inc still owns at least 18,943,802 units of BeiGene Ltd stock.

You can see the complete history of Inc Amgen stock trades at the bottom of the page.

What's Inc Amgen's mailing address?

Inc's mailing address filed with the SEC is ONE AMGEN CENTER DRIVE, , THOUSAND OAKS, CA, 91320.

Insiders trading at BeiGene Ltd

Over the last 9 years, insiders at BeiGene Ltd have traded over $1,899,158,980 worth of BeiGene Ltd stock and bought 23,241,738 units worth $1,040,248,444 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Investment Management, Ltd.... e Bros. Advisors Lp Baker Bro.... On average, BeiGene Ltd executives and independent directors trade stock every 13 days with the average trade being worth of $33,382,815. The most recent stock trade was executed by Xiaobin Wu on 3 September 2024, trading 5,556 units of BGNE stock currently worth $1,053,695.

What does BeiGene Ltd do?

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.

Complete history of Inc Amgen stock trades at BeiGene Ltd

BeiGene Ltd executives and stock owners

BeiGene Ltd executives and other stock owners filed with the SEC include:

• John Oyler,
  Co-Founder, Executive Chairman of the Board, Chief Executive Officer
• Xiaodong Wang,
  Co-Founder, Non-Executive Director
• Dr. Xiaodong Wang Ph.D.,
  Co-Founder, Chairman of the Scientific Advisory Board & Non-Exec. Director
• John V. Oyler,
  Co-Founder, Exec. Chairman & CEO
• Dr. Xiaobin Wu Ph.D.,
  Pres, COO & GM of China
• Wang Lai,
  Global Head of R&D
• Dr. Edna Huang M.D.,
  Chief Medical Officer of Hematology
• Dr. Jane Edna Huang M.D.,
  Chief Medical Officer of Hematology
• Dr. Heng Liang,
  CFO & Chief Strategy Officer
• Thomas Malley,
  Non-Executive Independent Director
• Qingqing YI,
  Non-Executive Independent Director
• Timothy Chen,
  Non-Executive Independent Director
• Jing-Shyh Su,
  Non-Executive Independent Director
• Donald Glazer,
  Non-Executive Independent Director
• Ranjeev Krishana,
  Non-Executive Independent Director
• Michael Goller,
  Non-Executive Independent Director
• Corazon Sanders,
  Non-Executive Independent Director
• Anthony Hooper,
  Non-Executive Director
• Hing Ling Chau,
  Company Secretary
• Jane Huang,
  Chief Medical Officer, Hematology
• Xiaobin Wu,
  General Manager - China, President
• Kevin C. Mannix,
  Sr. VP of Investor Relations.
• Mi Zhou,
  Sr. Director of Investor Relations
• Julia Wang,
  CFO & Principal Accounting Officer
• Diana Lee Francis,
  VP and Global Head of Quality & Regulatory Compliance
• Scott Samuels,
  Sr. VP & Gen. Counsel
• Craig West CFA,
  Sr. Director of Investor Relations
• Michael Garvey,
  Global Head of Technical Operations
• Daniel Maller,
  VP of Fin. & Accounting
• Jianxin Yang,
  Sr. VP, Head of Clinical Dev.
• Amy C. Peterson,
  CMO, Immuno-oncology
• Ji Li,
  EVP and Gl. Head of Bus. Dev.
• Investment Management, Ltd....,
  10% owner
• Rui Rong Yuan,
  Chief Medical Officer
• Ke Tang,
  Director
• Bros. Advisors Lp Baker Bro...,
  
• Biotech Investment Ltd Cpe ...,
  
• Wendy Xiaojun Yan,
  Sr. VP, Head of Reg. Affairs
• & Co., Inc.Merck Sharp & Do...,
  
• Chan Henry Lee,
  SVP, General Counsel
• Bros. Advisors Lp14159, L.P...,
  
• Bros. Advisors Lp667, L.P.B...,
  
• Howard Liang,
  CFO & Chief Strategy Officer
• Inc Amgen,
  10% owner
• Lai Wang,
  Global Head of R&D
• Olivier Brandicourt,
  Director
• Julia Aijun Wang,
  Chief Financial Officer
• Margaret Dugan,
  Director
• Advisors, Ltd.Hillhouse Inv...,
  
• Bros. Advisors Lp667, L.P.B...,
  
• Titus B. Ball,
  Principal Accounting Officer
• Aaron Rosenberg,
  Chief Financial Officer